Epstein-Barr Virus Driven Hodgkin's Lymphoma after a Short Course of Daratumumab Treatment for Relapsed Multiple Myeloma.

Authors :: Mohammadi-Oroujeh M
Mehreen A
Grinblatt DL
Source :: Case reports in hematology [Case Rep Hematol] 2023 Dec 18; Vol. 2023, pp. 6669174. Date of Electronic Publication: 2023 Dec 18 (Print Publication: 2023).
Publication Year :: 2023
Abstract: In this case, we describe the potential risk of developing an infectious complication leading to a secondary malignancy after a short course of immunotherapy. We report a patient who presented with Epstein-Barr virus (EBV) driven Hodgkin's lymphoma after treatment with a short course of daratumumab along with pomalidomide and dexamethasone for relapsed multiple myeloma. Although there have been limited documented cases of daratumumab treatment leading to EBV reactivation, in patients presenting with infectious symptoms or neutropenia on a daratumumab-based regimen, testing for EBV should not be overlooked.<br />Competing Interests: DLG is a consultant for Bristol-Myers Squibb. Remaining authors declare that they have no conflicts of interest.<br /> (Copyright © 2023 Moeen Mohammadi-Oroujeh et al.)

Full Text Access

Tools